Allogeneic hematopoietic cell transplantation with a combination of posttransplantation bendamustine and cyclophosphamide in refractory myeloid neoplasms DOI
Ivan Moiseev, Sergey N. Bondarenko, Yulia Vlasova

et al.

Cancer, Journal Year: 2025, Volume and Issue: 131(10)

Published: May 15, 2025

Abstract Background Prognosis after salvage allogeneic hematopoietic cell transplantation (HCT) in refractory myeloid malignant diseases is poor with no standard of care. Methods A prospective single‐arm study was conducted to evaluate if a combination posttransplantation bendamustine and cyclophosphamide (PTBCy) facilitates augmented graft‐vs‐leukemia effect this group patients. The (NCT04943757) HCT from all types donors enrolled 50 patients neoplasms. Results Cumulative incidence engraftment 88%; 76% had measurable residual disease. Immune toxicity the form cytokine release syndrome observed 30%. acute graft‐vs‐host disease (GVHD) Grade 2 through 4 20%. moderate severe chronic GVHD 34%. Nonrelapse mortality Relapse 62%, but median time relapse 245 days. Overall survival 33% event‐free 22%. In multivariate analysis alternative donor (hazard ratio, 0.24; 95% CI, 0.11–0.52) adverse genetic features 2.48; 1.26–4.88) were significant. PTBCy regimen associated unique immune reconstitution pattern high levels CD8+ effector memory T cells, PD‐1L–positive monocytes, granulocytes. Conclusions prophylaxis promising approach for neoplasms, which delays opens window posttransplant prophylaxis.

Language: Английский

Microenvironment-based immunotherapy in oral cancer: a comprehensive review DOI

Hassan Mivehchi,

Aisan Eskandari-Yaghbastlo,

Masumeh Ghazanfarpour

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(5)

Published: March 28, 2025

Language: Английский

Citations

2
New perspectives on gastric disorders: the relationship between innate lymphoid cells and microbes in the stomach DOI Creative Commons
Yunzi Yan, Naoko Satoh‐Takayama

Cellular and Molecular Life Sciences, Journal Year: 2025, Volume and Issue: 82(1)

Published: March 13, 2025

A growing number of studies in recent years have revealed the changes gastric microbiota during development diseases, breaking stereotype that stomach is hostile to microorganisms beyond H. pylori. After a decade intensive research, discovery innate lymphoid cells (ILCs) has provided new perspective on immune response many diseases. In context defense against infectious pathogens, pre-existing mechanism tissue-resident ILCs can rapidly recognize and respond microbes eliminate infection at earliest stages. Here, we outline basic function mucosa shaping microbiome. We discuss interactions between ILCs, explaining how actively drive bacterial pathogens lead disease.

Language: Английский

Citations

0
Circulating innate lymphoid cells are dysregulated in patients with prostate cancer DOI Creative Commons

Daniela Claudia Maresca,

Evelina La Civita,

Benedetta Romano

et al.

Cellular & Molecular Biology Letters, Journal Year: 2025, Volume and Issue: 30(1)

Published: April 18, 2025

Language: Английский

Citations

0
Allogeneic hematopoietic cell transplantation with a combination of posttransplantation bendamustine and cyclophosphamide in refractory myeloid neoplasms DOI
Ivan Moiseev, Sergey N. Bondarenko, Yulia Vlasova

et al.

Cancer, Journal Year: 2025, Volume and Issue: 131(10)

Published: May 15, 2025

Abstract Background Prognosis after salvage allogeneic hematopoietic cell transplantation (HCT) in refractory myeloid malignant diseases is poor with no standard of care. Methods A prospective single‐arm study was conducted to evaluate if a combination posttransplantation bendamustine and cyclophosphamide (PTBCy) facilitates augmented graft‐vs‐leukemia effect this group patients. The (NCT04943757) HCT from all types donors enrolled 50 patients neoplasms. Results Cumulative incidence engraftment 88%; 76% had measurable residual disease. Immune toxicity the form cytokine release syndrome observed 30%. acute graft‐vs‐host disease (GVHD) Grade 2 through 4 20%. moderate severe chronic GVHD 34%. Nonrelapse mortality Relapse 62%, but median time relapse 245 days. Overall survival 33% event‐free 22%. In multivariate analysis alternative donor (hazard ratio, 0.24; 95% CI, 0.11–0.52) adverse genetic features 2.48; 1.26–4.88) were significant. PTBCy regimen associated unique immune reconstitution pattern high levels CD8+ effector memory T cells, PD‐1L–positive monocytes, granulocytes. Conclusions prophylaxis promising approach for neoplasms, which delays opens window posttransplant prophylaxis.

Language: Английский

Citations

0